PURPOSE: To evaluate the technical and clinical success of percutaneous superior mesenteric vein (SMV) stenting in symptomatic @entity1 using self-expanding @entity5648 stents. METHODS: We retrospectively analyzed the technical and clinical success of percutaneous SMV stenting of 6 symptomatic @entity1 (3 @entity1 , mean age 67 years, range 48-81 years). @entity850 of the SMV was caused by @entity86 (n=3), @entity788 (n=1) and @entity788 (n=2). As a result of the @entity850 , 3 @entity1 had symptomatic ascites, 2 @entity1 showed signs of @entity5327 and 1 @entity1 had recurrent @entity360 . Stenting was performed by a percutaneous transhepatic approach using self-expanding @entity5648 stents. RESULTS: Stenting of the SMV was technically and clinically successful in all @entity1 . No peri-interventional complications occurred. The stent diameters ranged from 6 to 14mm. During the mean follow-up of 6 months (range, 2-10 months) 1 @entity1 presented early stent occlusion 2 weeks after placement. CONCLUSION: Stenting of a symptomatic SMV @entity850 using self-expanding @entity5648 stents is feasible and clinically effective.

Percutaneous treatment of symptomatic superior @entity850 using self-expanding XXXX stents.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'pancreas carcinoma'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative stricture'] @entity850 :: ('MESH:D003251', 'Disease') :: ['Stenosis', 'stenosis'] @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal bleeding'] @entity5327 :: ('MESH:D065666', 'Disease') :: ['mesenteric ischemia'] @entity5648 :: ('MESH:C013616', 'Chemical') :: ['nitinol']
@entity5648 :: (MESH:C013616,Chemical) :: ['nitinol']
